CureVac' (CVAC) CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19

Go back to CureVac' (CVAC) CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19
Clearview Acquisitions, Inc. (NASDAQ: CVAC) Delayed: 4.66 --0 (-0%)
Previous Close $4.66    52 Week High $2.10 
Open $4.66    52 Week Low $1.50 
Day High $4.66    P/E N/A 
Day Low $4.66    EPS $-0.04 
Volume 80,677